Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05633407 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS
A Phase 2 study, sponsored by argenx.
- Completed
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
NCT05633407 is a Phase 2 study that has completed, run by argenx. The registered enrollment target is 53 participants.
The verdict
NCT05633407, a Phase 2 study, has completed, sponsored by argenx.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
Study Summary
The study aims to investigate the safety, tolerability, efficacy, pharmacodynamics (PD), pharmacokinetics (PK), and immunogenicity of efgartigimod compared to placebo in participants with post-COVID-19 postural orthostatic tachycardia syndrome (POTS) (post-COVID-19 POTS).
Interventions
- DRUG Placebo
- DRUG Efgartigimod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2022-09-23 |
| Est. Completion | 2024-04-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05633407
The ClinicalTrials.gov registry entry for NCT05633407 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is argenx, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05633407 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05633407 about?
NCT05633407 is a clinical study titled "Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS". The study aims to investigate the safety, tolerability, efficacy, pharmacodynamics (PD), pharmacokinetics (PK), and immunogenicity of efgartigimod compared to placebo in participants with post-COVID-19 postural orthostatic tachycardia syndrome (POTS) (post-COVID-19 POTS).
What is the current status of trial NCT05633407?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2022-09-23. Estimated completion is 2024-04-18.
What interventions are being tested in trial NCT05633407?
The interventions under investigation include: Placebo (DRUG), Efgartigimod (DRUG).
Who is sponsoring clinical trial NCT05633407?
This trial is sponsored by argenx, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.